Written and Reviewed by Team Pharmacally
Precision oncology, a rapidly expanding discipline of medicine, focuses on personalizing cancer treatment to the genetic, molecular, and cellular aspects of an individual’s tumor. Over the past two decades, tremendous discoveries have changed our understanding and treatment of cancer. This article examines the significant accomplishments and ongoing difficulties in this revolutionary sector.
The Evolution of Precision Oncology
Precision oncology has its roots in the Human Genome Project, which was completed in 2003. This enormous accomplishment opened the door to a better comprehension of the genetic causes of cancer. Progress was further expedited with the introduction of next-generation sequencing (NGS) technology, which allowed scientists to examine tumors in previously unheard-of depth.
The discovery of actionable genetic alterations constituted a turning point in precision oncology. Treatments such as trastuzumab (Herceptin) for HER2-positive breast cancer and imatinib (Gleevec) for chronic myeloid leukemia (CML) showed that focusing on particular genetic abnormalities could produce impressive therapeutic results. The foundation for a new era in cancer treatment was established by these achievements.
Recent Advancements in Precision Oncology
Comprehensive Genomic Profiling (CGP):
CGP makes it possible to analyze several genes linked to cancer at once. New therapeutic targets have been found as a result of this strategy, and biomarker-driven treatments have been created.
Liquid Biopsies:
Cancer monitoring and diagnosis have been revolutionized by non-invasive liquid biopsies, which identify circulating tumour DNA (ctDNA) and other biomarkers in blood. They enable early diagnosis of resistance and illness recurrence by offering real-time insights into tumor dynamics.
Immuno-oncology and Precision:
Combining immunotherapy and precision medicine has showed potential in using the immune system to combat cancer. Immunocheckpoint inhibitor selection is guided by biomarkers including microsatellite instability (MSI) status and PD-L1 expression, providing individualized therapeutic options.
AI and Machine Learning:
The use of machine learning and artificial intelligence (AI) to evaluate intricate genomic data, forecast treatment outcomes, and improve clinical trial designs is growing. Precision oncology is becoming more accurate and efficient because of these tools.
Targeted and Combination Therapies:
Advances in drug development have led to the emergence of highly precise medicines targeting mutations such as EGFR, ALK, and BRAF. Combination medicines, which attack many routes simultaneously, are showing promise in overcoming resistance mechanisms.
Challenges in Precision Oncology
Despite impressive advancements, a number of obstacles still exist:
Tumor Heterogeneity: Treatment approaches are made more difficult by the fact that tumours frequently display genetic and molecular variation within the same patient.
Equity and Access: Many patients’ access is restricted by the high expense of targeted medicines and genomic testing, especially in countries with limited resources.
Mechanisms of Resistance: Targeted therapy may cause tumors to become resistant, thus further study is necessary to keep up with these changes.
Data Integration: Handling and analyzing the enormous volumes of data produced by genetic research is a difficult task that calls for a strong infrastructure and multidisciplinary cooperation.
Future Directions
Collaboration and ongoing innovation are key to precision oncology’s future. Key areas of attention consist of:
Pan-Cancer Strategies: Using shared biological pathways among many cancer types to create treatments that work for everyone. In order to develop a comprehensive understanding of cancer biology, multi-omics integration combines genomes, proteomics, metabolomics, and other “omics” technologies.
Customized vaccinations: Creating cancer vaccinations based on a person’s tumor neoantigens
Global Initiatives: Reducing gaps in cancer care by extending access to precision oncology through international partnerships and initiatives.
Established Precision Oncology Drugs
Customizing cancer treatment to the unique genetic, molecular, and cellular features of each patient’s tumor is known as precision oncology. The following list of well-known precision oncology medications is arranged according to the genetic alterations or biomarkers they target:
EGFR Mutations (Epidermal Growth Factor Receptor)
Gefitinib (Iressa), Erlotinib (Tarceva), Afatinib (Gilotrif): First-generation EGFR inhibitors.
Osimertinib (Tagrisso): Targets EGFR T790M mutation and is also used as a first-line therapy in advanced non-small cell lung cancer (NSCLC).
Indication: Non-small cell lung cancer (NSCLC) with EGFR mutations.
ALK Rearrangements (Anaplastic Lymphoma Kinase)
Crizotinib (Xalkori): First-generation ALK inhibitor.
Alectinib (Alecensa), Brigatinib (Alunbrig), Lorlatinib (Lorbrena): Next-generation inhibitors with enhanced efficacy and blood-brain barrier penetration.
Indication: NSCLC with ALK gene rearrangements.
HER2 Amplifications (Human Epidermal Growth Factor Receptor 2)
Trastuzumab (Herceptin), Pertuzumab (Perjeta): Monoclonal antibodies targeting HER2.
T-DM1 (Kadcyla): Antibody-drug conjugate for HER2-positive breast cancer.
Trastuzumab deruxtecan (Enhertu): Antibody-drug conjugates with potent efficacy in HER2-positive cancers.
Indication: HER2-positive breast cancer, gastric cancer, and others.
BRAF Mutations (V600E Mutation)
Vemurafenib (Zelboraf), Dabrafenib (Tafinlar): BRAF inhibitors.
Combination therapy: Dabrafenib + Trametinib (Mekinist) (MEK inhibitor).
Indication: Melanoma, NSCLC, and anaplastic thyroid cancer with BRAF V600E mutations.
BRCA1/BRCA2 Mutations
Olaparib (Lynparza), Rucaparib (Rubraca), Niraparib (Zejula), Talazoparib (Talzenna): PARP inhibitors.
Indication: Breast, ovarian, prostate, and pancreatic cancers with BRCA mutations.
.NTRK Fusions (Neurotrophic Tyrosine Receptor Kinase)
Larotrectinib (Vitrakvi), Entrectinib (Rozlytrek): Selective NTRK inhibitors.
Indication: Tumors with NTRK gene fusions, regardless of tissue origin.
PD-1/PD-L1 Expression (Immune Checkpoint Inhibition)
Pembrolizumab (Keytruda), Nivolumab (Opdivo): PD-1 inhibitors.
Atezolizumab (Tecentriq), Durvalumab (Imfinzi): PD-L1 inhibitors.
Indication: Tumors with high PD-L1 expression, microsatellite instability-high (MSI-H), or mismatch repair deficiency (dMMR).
KRAS G12C Mutations
Sotorasib (Lumakras), Adagrasib (Krazati): KRAS G12C inhibitors.
Indication: NSCLC, colorectal cancer, and other KRAS G12C-mutated cancers.
These drugs highlight the shift toward molecularly targeted therapies, emphasizing the importance of genetic testing and biomarker identification in cancer care.
Conclusion
Precision oncology has fundamentally changed the landscape of cancer treatment, offering hope to millions of patients worldwide. While significant challenges remain, ongoing advancements in technology, biology, and data science promise to further refine and expand the impact of personalized cancer care. As we stand on the cusp of new discoveries, the journey of precision oncology continues to inspire optimism and determination in the fight against cancer.
References:
1. Liu X, Wang P, Zhang C, Ma Z. Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer. Oncotarget. 2017 Jul 25;8(30):50209-50220. Doi: 10.18632/oncotarget.16854. PMID: 28430586; PMCID: PMC5564844.
2. V. Subbiah, S. Kuravi, S. Ganguly, D.R., et al,Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma, ESMO Open, Volume 6, Issue 4, 2021,100172, https://doi.org/10.1016/j.esmoop.2021.100172.
3. Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, Srock S, Bardelli A, Trusolino L. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018 May 1;29(5):1108-1119. Doi: 10.1093/annonc/mdy100. PMID: 29659677; PMCID: PMC5961091.
4. Gouda MA, Subbiah V. Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy. ESMO Open. 2023 Apr;8(2):100788. Doi: 10.1016/j.esmoop.2023.100788. Epub 2023 Feb 24. PMID: 36842301; PMCID: PMC9984800.
5. Katherine I. Zhou et al., Real-world Experience with Neurotrophic Tyrosine Receptor Kinase Fusion–positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans. JCO Precis Oncol7, e2200692(2023). DOI:1200/PO.22.00692
6. Lee Schwartzberg, MD, Edward S. Kim, MD, David Liu et al, Precision Oncology: Who, How, What, When, and When Not?, 2017 Asco Educational Book
7. Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L, Wang S. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022 Sep 13; 13:964442. Doi: 10.3389/fimmu.2022.964442. PMID: 36177034; PMCID: PMC9513184.
8. Kunjing Liu, Qi Sun, Qi Liu, Huayao, et al, Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy, Biomedicine & Pharmacotherapy, Volume 154, 2022, 113618, https://doi.org/10.1016/j.biopha.2022.113618.
9. Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res. 2008 Dec 15; 14(24):7988-99. Doi: 10.1158/1078-0432.CCR-08-1211. PMID: 19088015; PMCID: PMC4535810.
10. Samstein RM, Krishna C, Ma X, et al, Mutations in BRCA1and BRCA2differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nat Cancer. 2021 Dec;1(12):1188-1203. Doi: 10.1038/s43018-020-00139-8. Epub 2020 Nov 16. PMID: 33834176; PMCID: PMC8023400.
11. Di Nicolantonio, F., Bardelli, A. Precision oncology for KRASG12C-mutant colorectal cancer. Nat Rev Clin Oncol20, 355–356 (2023). https://doi.org/10.1038/s41571-023-00748-z
12. Hofmann MH, Gerlach D, Misale S, Petronczki M, Kraut N. Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer Discov. 2022 Apr 1;12(4):924-937. Doi: 10.1158/2159-8290.CD-21-1331. PMID: 35046095; PMCID: PMC9394389.
13. Sattler, Martin et al., Precision oncology provides opportunities for targeting KRAS-inhibitor resistance, Trends in Cancer, Volume 9, Issue 1, 42 – 54
14. Pankiw M, Brezden-Masley C, Charames GS. Comprehensive genomic profiling for oncological advancements by precision medicine. Med Oncol. 2023 Nov 22; 41(1):1. Doi: 10.1007/s12032-023-02228-x. PMID: 37993657.
15. Comprehensive Genomic Profiling (CGP): Accelerating Progress in Precision oncology, Thermo fisher Scientific, Precision Oncology.
16. Comprehensive Genomic Profiling Improves Precision Therapy Use and Patient Survival, Asco Daily News, Published on 12 November 2024
17. Caputo V, Ciardiello F, Corte CMD, Martini G, Troiani T, Napolitano S. Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer. Explor Target Antitumor Ther. 2023; 4(1):102-138. Doi: 10.37349/etat.2023.00125. Epub 2023 Feb 28. PMID: 36937316; PMCID: PMC10017193.
18. Erick F. Saldanha, Eleonora Nicolo, Konstantinos Venetis, Diego de Miguel-Perez, Ana Ortega-Franco, Angelo Dipasquale, Mohamed A. Gouda, Surbhi Singhal, George Adigbli, Carolina Reduzzi,
19. The role of liquid biopsy as a catalyst for sustained progress in precision oncology – Perspective of the young committee of the international society of liquid biopsy, The Journal of Liquid Biopsy, Volume 5, 2024, 100156, https://doi.org/10.1016/j.jlb.2024.100156
20. The future of cancer treatment, Centre for Immunotherapy and precision immune-oncology, Cleveland Clinic, Lerner Research Institute
21. Scheuenpflug J. Precision Medicine in Oncology and Immuno-Oncology: Where We Stand and Where We’re Headed. Biomed Hub. 2017 Nov 21;2(Suppl 1):79-86. doi: 10.1159/000481878. PMID: 31988938; PMCID: PMC6945891.
22. Wei L, Niraula D, Gates EDH, Fu J, et al., Artificial intelligence (AI) and machine learning (ML) in precision oncology: a review on enhancing discoverability through multiomics integration. Br J Radiol. 2023 Oct;96(1150):20230211. doi: 10.1259/bjr.20230211. Epub 2023 Sep 3. PMID: 37660402; PMCID: PMC10546458.
23. Perez-Lopez, R., Reis-Filho, J.S. & Kather, J.N. A framework for artificial intelligence in cancer research and precision oncology. npj Precis. Onc. 7, 43 (2023). https://doi.org/10.1038/s41698-023-00383-y
24. Bhalla S, Laganà A. Artificial Intelligence for Precision Oncology. Adv Exp Med Biol. 2022; 1361:249-268. Doi: 10.1007/978-3-030-91836-1_14. PMID: 35230693.
25. Ding MQ, Chen L, Cooper GF, Young JD, Lu X. Precision Oncology beyond Targeted Therapy: Combining Omics Data with Machine Learning Matches the Majority of Cancer Cells to Effective Therapeutics. Mol Cancer Res. 2018 Feb; 16(2):269-278. Doi: 10.1158/1541-7786.MCR-17-0378. Epub 2017 Nov 13. PMID: 29133589; PMCID: PMC5821274.
26. Sara S Bashraheel, Alexander Domling, Sayed K Goda,Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine, Biomedicine & Pharmacotherapy, Volume 125, 2020, 110009, https://doi.org/10.1016/j.biopha.2020.110009.
27. Targeted Therapy & Precision Oncology, Memoir Sloan Kettering Cancer Centre
28. Fountzilas E, Tsimberidou AM. Overview of precision oncology trials: challenges and opportunities. Expert Rev Clin Pharmacol. 2018 Aug;11(8):797-804. doi: 10.1080/17512433.2018.1504677. Epub 2018 Aug 10. PMID: 30044653; PMCID: PMC6330881.
29. Yang HT, Shah RH, Tegay D, Onel K. Precision oncology: lessons learned and challenges for the future. Cancer Manag Res. 2019 Aug 7;11:7525-7536. Doi: 10.2147/CMAR.S201326. PMID: 31616176; PMCID: PMC6698584.
Add a Comment